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ABSTRACT
Dr. Irving Weissman was the honored E. Donnall Thomas lecturer at the Tandem BMT Meetings, held on
February 10, 2007, at Keystone, Colorado. Dr. Weissman has been a major player, and has provided us with
enormous insight into many areas of biology, dating back to his high school days in Montana. He led an
enormously productive career at Stanford University where he has taught us many lessons involving our under-
standing of lymphocyte homing, stem cell biology, both of the hematopoietic system and other types of stem
cells, and also now, about cancer stem cells. Dr.Weissman has made enormous contributions to this burgeoning
field that has provided us new insights and new opportunities for treatment strategies. In addition to a very
productive laboratory career, he is also currently the director of both the Stem Cell Institute, as well as the
Cancer Center at Stanford University. The following text is a modified transcribed version of the presentation
made by Dr. Weissman.
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In this presentation, I am going to talk about nor-
mal stem cells, hematopoietic stem cells, cancer stem
cells, and a little bit about brain stem cells, if I have
time. The point here is that we have known since
Till and McCulloch [1] that hematopoietic stem cells
must exist, and that the principle difference between
stem cells and their progenitors is that stem cells
self-renew (Figure 1). The general method that we
have used to isolate stem cells is to find surface markers
on stem cells, as positive selectors, and surface markers
on nonstem cells, as negative selectors, so that at the
end of the day you can get hematopoietic stem cells
free of other unwanted cells. Of course, if you have
cancer cells in the autologous transplant, you would
rather get rid of them so you could have a cancer-free
transplant. If you want to do allogeneic transplants,
not for malignant diseases, but for other conditions
where you want the donor cells to engraft without
graft-versus-host disease (GVHD), again I would ar-
gue that you would like to have pure stem cells. The
population of cells in the mouse that we found manyyears ago, that had the activity of clonal precursors of
all lineages of blood cells and at which at the single
cell level could give rise to long-term engraftment
and growth of about 30,000 stem cells from a single
cell for the life of the host, and the next host, and the
next host, had this set (Sca 1, Thy1.1, ckit) of positive
markers on the surface, and negative for any lineage
markers (lin2).
Now, as time has gone on, we have gotten better
and better, and we know that this population has other
markers on the surface by gene expression analysis.We
and Sean Morrison’s group [2,3], found other markers
that were on (eg, CD150 and ESAM1), and markers
that were off, and so one can now daily, if you have
a multicolor cell sorter, get those kinds of populations
of cells. And, we were also able in the 1980s to develop
mice that had human fetal bone, thymus, liver, and
spleen, and so we could irradiate and reconstitute those
mice, and using that as 1 of the assays, we were able to
isolate the human hematopoietic stem cell. It should be
noted that it is not just CD341, CD382, nor just
CD341. One of the important points, at least if you849
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CD341CD382Thy1lin2 cells. You can use ckit as
a marker, although it is not the most useful marker
because it is downregulated during mobilization, but
then the lin2 panel is very important, as well. Years
ago, at a company I cofounded, called SyStemix, the
population of cells in human mobilized blood that
were CD341Thy1 were used in many transplants in
humans, and this same population was depleted of
tumor cells.
Eli Hanania performed an experiment for SyS-
temix in the mid-1990s, where he added authentic
breast cancer cells or non-Hodgkin lymphoma (NHL)
or myeloma cells to mobilized blood so that 7 cells
per thousand nucleated cells were tumor cells. He
then ran the population through the cell sorter, and
the combination of flow sorting and multiple anti-
bodies purged the graft 250,000-fold if it was breast
cancer, 220,000-fold if it was NHL, and about
145,000-fold if it was myeloma. In contrast, the same
sorter with any single antibody alone or by any other
single antibody method would not purge the graft
Figure 1. Schematic of Hematopoiesis. HSC are the long-term self-
renewing cells that give rise to all mature blood cells through a
hierarchy of developmental intermediates including multipotent
progenitors (MPP), which have limited self-renewal and provide
transient but multilineage reconstitution, and increasingly lineage
restricted progenitors. CMP, common myeloid progenitor, CLP,
common lymphoid progenitor, BLP, B lymphocyte protenitor,
ProT, T cell progenitor, GMP, granulocyte/macrophage pro-
genitor, MEP, megakaryocyte/erythroid progenitor, MCP, mast
cell progenitor, MkP, megakaryocyte progenitor, EP, erythroid
progenitor.more than 100- or 1000-fold. Rob Negrin et al. [4]
led the clinical trial at Stanford started in 1996, and
showed a dose-response in myeloablated stage IV
breast cancer patients, accruing 22 patients by 1998,
15 at Stanford, and 7 at Detroit. The dose-response
characteristics pretty much mirrored what we had in
mice. That is, that syngeneic or autologous transplants
at a dose of 2  105 stem cells per kilogram body
weight would give you 10-13 days for white cells and
a prolonged time for platelets but anything above 8
 105 per kilo you averaged about 10 days for 500
white cells and 20,000 platelets. Those patients were
followed for at least 4 years, and displayed about
45% disease-free survival (DFS) at 3 years and 37%
at 4 years time.
Hematopoietic StemCell Transplantation (HSCT)
Rapid and sustained engraftment can occur in
humans with a stem cell transplant in an autologous
setting. You can deliver a cancer-free graft and then
decide whether that is important to what you are
doing. In mice, Judy Shizuru and I showed in sev-
eral experiments that even in the most aggressive
allogeneic setting of C57BL/6 transplantation into
BALB/c mice, with no MHC match, something
you would never do, that at the dose that a syngeneic
mouse gives you 22 days to engraftment, it takes an
allogeneic HSC transplant 10 times that dose,
a thousand cells [5]. However, by the time you get
to 10,000 cells in the allogeneic, it is equivalent to
5000 syngeneic or autologous cells; both engraft
platelets and neutrophils by 10 days. So, these re-
sults suggest, if mice and humans turn out to be
the same, that you could accomplish allogeneic en-
graftment. Now Judy Shizuru and I have lowered
that dose considerably by pretreating the host with
antibodies that are even more lymphoablative, so
they eliminate T cells and natural killer cells. And
you have to eliminate both of those if you have
a haploidentical or a fully allogeneic donor in this
setting.
In these pure HSC allotransplants, there was no
GVHD or residual host-versus-graft response, be-
cause there were no T cells in the transplant in these
mice. Shizuru and I went on to show, as did Kim
Gandy with me, that when you transplant C57BL/6
into BALB/c mice you can cotransplant the same
day or a year later, a heart or an islet, and they are
permanently tolerant [6,7]. We thought it would
just be a matter of a year or 2 before everybody would
try to use this for organ graft tolerance. Of course,
that did not happen right away, but I have been
known to be a little enthusiastic. When I was 16, in
Great Falls, Montana, I transplanted male bone mar-
row into female mice in Ernst Eichwald’s lab, and
showed that I could induce permanent transplant
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irradiation, and third-party grafts were rejected. So,
that day in 1957, I went home and told my mom,
‘‘it’s going to be just a matter of a couple of years be-
fore everybody is going to get organ transplants this
simple way.’’ The new setting of this approach is
that you can now do it under entirely nonlethal
conditions, where you lymphoablate and only myelo-
suppress the host, and you can get engraftment, long-
term chimerism, and graft acceptance without any
GVHD.
HSCTand Autoimmune Disease
Now, Shizuru went on with me and George Beil-
hack to look at type I diabetes, which, as you know, is
not a disease of the islets, but a disease of the immune
system [8]. And, just as you would like to treat sickle
cell, beta thalassemia, or severe combined immunode-
ficiency with stem cells that do not give GVHD, but
do engraft, type I diabetes is another disease that
may be correctable by giving hematopoietic stem cells
from a donor that is resistant to the developing auto-
immune disease. Nonobese diabetic (NOD) mice
develop type I diabetes at 5-6 months of age by an
autoimmune attack, and it is a multigenic disorder.
If we give them myeloablative conditioning, which is
also lymphoablative, and give back their bone marrow,
which has T cells in it, much like the Richard Burt
studies to reset the clock, I am told, the approach
buys you a couple of months. If you give back the
NOD, autologous stem cells alone buys you another
couple of months, but the genetic predilection of the
disease always comes back and the animals eventually
develop diabetes. However, if you give third-party
strain, AKR, which is distantly related but much
more relevant, transplant MHC H2g7 matched
HSC (these mice have at least 3 independent genes
that are resistance genes to diabetes), it is curative in
the polydypsic polyuric stage of the disease. All you
have to fix at that time, in these mice, is the autoim-
mune part of the disease and the islets regenerate.
The islets are still having infiltrative B cells, but not
T cells, and that does not lead to a progressive disease.
It is important to note that you can cure mice of
progression in this autoimmune disease in both the
myeloablative and the nonmyeloablative settings in
mice.
Shizuru went on to show, with me, that you can
cotransplant already diabetic mice at 6 months or so
(the most difficult thing about these experiments is
providing insulin every day), and cure them of their
autoimmune disease with stem cells, and of their islet
deficiency with islets from the same donor. If we had
a method of growing or getting islets more efficiently
this would be a good therapeutic chance. The trans-
plant can be done with total lymphoid irradiation(TLI) and antithymocyte globulin (ATG), a setting
that allows MHC matched HSC to engraft. Eventu-
ally, we think that we would be able to treat diabetic
patients. It would have to be in the nonmyeloablative
setting to compete with insulin as a treatment for these
patients.
Now, does it stop there? No. In experiments re-
cently published by Julie Christensen at Cellerant
[9], she used the NZB  NZW (NZBW) model for
lupus, in which as the mice age, they develop autoanti-
bodies, which include anti-DNA and antihistone anti-
bodies, and get glomerulonephritis, probably from
circulating immune complexes. In this myeloablative
trial with animals that were 73-79 days of age, Chris-
tensen et al. gave them a lethal split dose of irradiation,
and then transplanted them. The irradiation had
some deleterious effect in some of those animals, and
syngeneic transplantation did not, in this case, offer
an advantage. But haploidentical allogeneic stem cell
(DBA  C57BL)F1 mice, which share the H2d
haplotype but also have an unshared H2b haplotype,
were transplanted into an autoimmune [NZB(d) 
NZW(w)]F1 hybrid strain. So, to make it simpler, it
is a d  b into d  w transplant, like a haploidentical
situation within a family. These allogeneic trans-
planted recipients had a later onset of disease, and
many of them did not progress.When you look at their
proteinuria, from \100 mg per deciliter up to very
high proteinurias (.500 mg/dL), the syngeneic recip-
ients did not have many animals in the low proteinuria
class, whereas the haploallogeneic recipients had a lot
with\100,\8% with .500 mg/dL, and at the time
the age-matched control group all had high protein-
uria. What was true for proteinuria was also true for
circulating immune complexes. Now, can you do this
in a nonmyeloablative setting? To answer that ques-
tion, mice were given sublethal doses of irradiation af-
ter treatment with 2 doses of anti-T cell globulin, at
doses known to deplete all classes of T cells, and also
anti-asialoGM 1 antibody, which depletes NK cells.
Mice were treated at about 280 days of age, when
they already had extensive disease. Conditioning alone
was sufficiently immunosuppressive that it delayed the
progression of disease, but the allotransplant led to
a cure of the disease in many of the animals. And, again
their proteinuria at the high level was lowest in the
allotransplanted versus age-matched or the condi-
tioned-alone animals.
These were the 2 practical applications that we
have looked at in mouse preclinical testing. I believe
that it will be possible to have a protocol to go into
allogeneic transplants in humans. Obviously, autoim-
mune patients are about the hardest to do. So, you
would have to have proof of principle in patients who
needed to have a healthy hematopoietic system, like
in sickle cell, beta thalassemia, severe combined immu-
nodeficiency, or some other indication.
852 I. L. WeissmanNormal Stem Cells
I now want to discuss the origins of the blood-
forming system, because it gets at the cell types that
form it and it involves what has become conventional
wisdom. The very first site of blood formation in the
mouse, and in the human, is in the yolk sac blood is-
lands. Mesodermal precursors migrate out into the
visceral entoderm and form islands of blood inside
and blood vessel outside. They connect up to each
other and then they form the vitelline vasculature
that connects up with the dorsal aorta. The first site
of appearance of hematopoiesis within the embryo
starts in the yolk sac, goes to the dorsal aorta, and
although nobody quotes it, we showed in 1975-1978
that you could transplant yolk sac blood islands from
previtelline vasculature connection embryos into the
yolk sac cavity of others and they were chimeric for
life, including hematopoietic stem cells and T cells.
The establishment of that primitive hematopoietic
system is the precursor of the establishment of the de-
finitive hematopoietic system. Since then, a number of
people, especially Gordon Keller, [10,11] have shown
that a cell called the hemangioblast, that he had puri-
fied to a single cell level from ES cells, can give rise to
blood and blood vessel cells. So it is now conventional
wisdom that the hemangioblast is the necessary pre-
cursor of hematopoietic and endothelial cells. Backing
that belief were the experiments where a VEGF recep-
tor called Flk-1 is knocked out in mice. Flk-1 is on
the hemangioblast and flk-1 knockout mice develop
neither blood nor blood vessels. However, a gene
knockout does not tell you the lineage relationship
between cells, and the presence of a hemangioblast
in an embryonic stem cell culture does not mean it is
necessarily the cell type that gives rise to blood and
blood vessels. Therefore, Hiroo Ueno and I [9] asked
whether yolk sac blood islands, when they arise, are
from a single cell, and if they are from a single cell,
are they from a hemangioblast. And the method we
used to test it was to make embryonic stem cells that
had different colors.
We made, by gene knock-in to the rosa locus,
a blue fluorescent protein encoding gene, green fluo-
rescent protein, and red ES cells, each expressing
only the color they should [12]. We injected those
into the blastocysts of uncolored mice, implanting
them in the uterus, and we thus generated tetra-chime-
ric mice. Using about 20 uncolored ES cells and ex-
actly 5 each of the 3 different colored ES cells, 4 days
later, the embryo had developed 3 germ layers and in
the visceral endoderm we could detect the first blood
island forming. The cells migrating up are polyclonal
in mice where there are clonal organizations of epithe-
lial cells. Without going through all the data in detail,
I will just say there were no clonal blood islands from
a common hemangioblast. None. There were nobiclonal yolk sac blood islands with a single endothelial
precursor and a single hematopoietic precursor
forming it. About 20% of the blood islands could be
explained by hemangioblasts participating in a poly-
clonal seeding, but 80% had no relationship between
blood and blood vessel in this polyclonal blood island
at the time they first formed. We included a flk-1
marking system so that if a cell turned on flk-1, the
cell changed its color, and again only 20% of the blood
cells in the organism went through a flk-1-positive
intermediate.
We can conclude then that the beginnings of the
blood-forming system in the yolk sac are polyclonal,
and although some cells could be derived from heman-
gioblasts, the vast majority are not. Now, those chime-
ric animals are useful to look at other organs. First,
throughout the endoderm, from the tongue to the rec-
tum, what you can see is that both the filiform papillae
in the tongue and the villae in the small intestine are
derived from a single cell. They are all blue, all green,
all red, or all uncolored. The second point is that if you
look at an adult chimeric mouse, cut a section through
the crypts where the stem cells are supposed to be, one
can see dozens of villi that are formed from a single gut
stem cell. This observation does not correlate with the
current conventional wisdom that the 4th cell up
around is a stem cell and it regenerates the villous. It
is not proof that it is not true, but it is not consistent
with it. The fact that you only have single colored
crypts whenever you look at an animal means that
you are not replacing it, turning it over, with external
stem cells. So, it is a stem cell system. I will not go
into all the other tissues, but I will just say that in the
liver you have a clonal organization all coming out
from the portal vein, and the colors stay consistent go-
ing out from the portal vein; whether those are stem or
progenitors, we do not know.
Hematopoiesis
I hinted to you that there were several migrations
to form the blood-forming system. A migration from
the mesenchyme to the yolk sac, from the yolk sac to
the dorsal aorta, and from the dorsal aorta to the fetal
liver. The liver gives out during fetal life and they go to
the bone marrow. So, migration is critical for each of
the steps of movement of hematopoietic stem cells
during the developmental process, and migration
continues at a pace none of us really suspected, unless
our interpretation of this experiment is wrong. Doug
Wright and I did several experiments following up
2 beautiful findings: 1 by Joan Goodman and George
Hodson in 1962, that the hematopoietic capacity for
restoration of the blood was about a thousandth of
that of the bone marrow, but it was there [13]. Then,
of course, the BMTfield contributed to the knowledge
that you can mobilize stem cells frommarrow to blood
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factor (G-CSF) [14-16].
Now, the amazing thing, if you think about it, is
that the first bone marrow transplant worked. Cells
that were resident in the bone marrow and placed,
not put it in the bonemarrow, but into the vascular sys-
tem, found their way to the radiated hematopoietic
bone marrow and engrafted there. I would argue
from that observation that there had to be a system al-
ready in place for cells that were in the blood, Good-
man’s very tiny number, to go to the bone marrow.
To make a long story short, we found that there are
steady-state 100 hematopoietic stem and multipotent
cells in the blood of the mouse. And, that when we iso-
lated those stem cells and put them into the blood
stream their residence time in the blood streamwas be-
tween 1 and 5 minutes. We tracked them with lucifer-
ase, thanks to a lot of work by Rob Negrin and Chris
Contag, and we found they homed to bone marrow,
liver, and spleen—the hematopoietic foci in a mouse
[17]. They did not stop in the lung; the only cell that
I have ever injected that did not get stuck in lung capil-
laries. Well, given even a 5-minute residence time to
maintain 100 hematopoietic stem cells in the blood
you have to flux 30,000 hematopoietic stem/progeni-
tor cells through the blood every day.
So, now it is 1 of the biggest recirculating systems
we can imagine. With that knowledge we went back
and looked at those experiments where people said
brain cells could give rise to stem cells that could
give rise to brain and blood, muscle stem cells could
give rise to muscle and blood. And, it was always sep-
arate hematopoietic stem cells and muscle stem cells,
or hematopoietic stem cells and brain stem cells. The
presence of all those circulating hematopoietic stem
cells was very curious, and there is a lot of things that
come from this. We know by parabiosis that the ones
that cross in the blood establish themselves as grafts
in the bones. So, they participate in hematopoiesis.
What happens when they become malignant? Well,
you have a malignancy of a cell that is spreading
throughout the bone marrow cavity. You have never
seen a myelogenous leukemia that is in 1 bone only,
so that you could just cut off the arm or irradiate it
and cure the disease. And, I would say you have not
seen it because you are looking at the normal property
of the precursors that become leukemic. Using migra-
tion, integrin a4b1 and SDF 1 find their way back to
the hematopoietic site. It has a lot to do with niches
and what we think niches are, because a lot of the cells
in that traffic will be near blood vessels and others will
be near other sites. It also has a lot to do with trying to
figure out what the steps are in forming those niches.
How about the next step down? We know long-term
stem cells give rise to short-term stem cells, then
they have a decision to lymphoid or myeloid. You
might have hoped to work it out in the microanatomyof the bone marrow, but if the cells on average leave 1
site and then enter at another site, they may find an-
other niche that is a myeloid or a lymphoid niche. It
is curious that HSCs and inflammatory T cells both
express integrin a4b1 [18,19] and home to SDF1
[20]. Perhaps a subset of HSC in circulation enter
VCAM11 vessels in inflamed tissues, there to respond
to local signals for direct bursts of myelomonocytic
cells.
In an experiment by Yuan Cao, Amy Wagers,
Chris Contag, and myself [17], a single visually ob-
served hematopoietic stem cell from a luciferase-posi-
tive animal was injected with host cells, and in different
hosts hematopoietic foci that go from the spleen to the
vertebrae, those that stay in the vertebrae, or those that
reach the skull and develop several independent foci,
resulted, consistent with the recircularory property
of these cells. Thinking about this observation, he be-
gan to examine howmany empty niches there are in the
bone marrow, because if they are going out they must
leave a niche and when they come back they fill the
niche. So, Deepta Battacharya injected a large number
of hematopoietic stem cells, up to 5000 of them, into
a syngeneic animal that differed either only by the
Ly5 allele or a green fluorescent protein (GFP) in
the donor, not the host [21]. None of those grafts
worked, because of rejection—even the tiniest differ-
ences were seen by an intact host and led to rejection
of the hematopoietic stem cells. So, he then moved
on to severe combined immunodeficient recipient
mice, and he found that a single injection of 250 hema-
topoietic stem cells fills about a 0.5%of the niches, and
cures the animal by 6 weeks of its immunodeficiency.
Although these mice only produced about 0.5% of
the myeloid cells from the donor, donor cells sustain
the production of both T and B cells, because there
is no competition for B cell and T cell niches; all as-
pects of their immune system are normal. When he
did the experiment he actually went from 0 cells to
5000 cells and found that he saturated the open 0.5%
of niches with the single bolus injection of 250 cells.
However, if he gave 250 cells a day apart, the next
day the niches are open again and so he gets a 0.5%
from each. So, there may be something there about
slow opening of niches and maybe slow infusion of
stem cells, but I will not go that far yet.
So far, I’ve told you that hematopoietic stem cells
self-renew, we have prospectively isolated them, and
with a number of people in the lab and a number of
people in other labs have found that there are least 2
downstream multipotent cells that hardly self-renew.
One, the short-term stem cells is present at 6 weeks;
the next 1 down, a multipotent cell, is there for\2
weeks. At the single cell level these multipotent cells
give robust engraftment and multilineage engraft-
ment, but they do not self-renew. They never go
back even a single step no matter how many cells
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that, they go either to the lymphoid or the myeloid
progenitor, erythrocyte progenitors go another way.
We can prospectively isolate each of those
populations and they do what their name says they
do, make myeloid cells, lymphocytes, or erythro-
cytes, and that they do it with very high efficiency.
The only cell that permanently self-renews in the he-
matopoietic system is the long-term hematopoietic
stem cell, which keeps migrating in and out of its
niches.
Aging and Myelopoiesis
Next, we wanted to look at what are the precondi-
tions that lead to leukemia and at what stage of devel-
opment do the leukemias break out. Is it a known stage
or is it a mixture . . . a mixed phenotype? And, does
a cell that never self-renewed now gain self-renewal ca-
pacity to be a leukemia stem cell? Some of the experi-
ments on the way turned out to be very interesting.
First, Sean Morrison and I, and then again recently
Derrick Rossi and I, looked at the aging of stem cells,
and here is what happens to them [22-24]. From
2-month to 2-year-old mice, stem cells actually in-
crease their number dramatically—maybe 20-fold.
A 2-year-old mouse, like a very old human, does not
make many new lymphocytes, but still makes lots of
myeloid cells. Usually, there is an anemia of aging, of
red cells, but you can have too many platelets.
Certainly that is the phenotype of the aged mouse.
WhenDerrick, David Bryder, and I transplanted equal
transplantable units of purified hematopoietic stem
cells, young and old, into the same young mouse, the
cells from old mice gave rise to 20-fold the number
of stem cells, decreased numbers of lymphocytes, and
lots of myeloid cells, whereas in the same microenvi-
ronment, the young cells gave rise to lots of myeloid,
lots of lymphoid, and notmanymore stem cells. So, ev-
ery property that we were looking at was intrinsic to
the transplanted hematopoietic stem cells. Our early
experiments with Uchida [25] showed that in adult
mice no cells other than HSC give rise to HSC, and
probably from early fetal life on there are only the orig-
inal clones of HSC and their progeny that sustain he-
matopoiesis. These clones change properties as they
go through their self-renewing divisions. The changes
they go through are not random. They may look ran-
dom, but they always lose lymphopoiesis and always
gain myelopoiesis in aging mice.
Considering that the shift toward myelopoiesis is
intrinsic, we studied the gene expression profile at
the level of the purified long-term stem cells, and we
found that the transcription factors for myelopoiesis
were up and others for lymphoid development were
down [23]. There is a correlation of the fate of the cells
and the transcription factors they are expressing at thelevel of the hematopoietic stem cell. Thus, very distant
fates are proscribed already at the level of the stem cell.
We published something like that in 1990 for fetal life
as well [26]. Looking at the names of some of thosemy-
eloid genes that are overexpressed, out of the top 32, 17
have been involved in translocations, duplications, or
inversions in human acute myelogenous or pro-
myelocytic leukemia. That led to a speculation that
these translocations were probably at loci that are
transcriptionally active rather than transcriptionally
silent. The fact that some genes on different chromo-
somes that are linked together in transcriptional foci
[27] will lead us to test whether among the transcrip-
tionally active genes if there is random translocation
or not.
Now, there is accelerated aging in a number of
progeria syndromes. Derrick picked 3 to study that in-
volved errors in repair of DNAdamage, because he fig-
ured that accumulated DNA damage might play a role
in aging [24]. That is a popular hypothesis. So, we had
defective nucleotide excision repair mice, XPD, we
had mice that lacked the RNA component of their tel-
omerase, so they cannot extend their telomers effi-
ciently. We had mice that lacked Ku 80, a protein
that binds to blunt end DNA double-strand breaks,
and then through H2 AX and other proteins is in-
volved in signaling the repair process. The big shock
is that these animals as they age did not selectively
lose their hematopoietic stem cells. However, of the
long-term hematopoietic stem cells, only 1% to 4%
go into cell cycle per day, whereas for theMPPs, about
15% to 20% of theirmultipotent progeny go into cycle
every day. Therefore, a lot of those cells could have
been hanging around without going into cell cycle.
When we put them into protocols to test their activity
and when we transplanted them, the age-matched stem
cells from those 3 diseases—the Tert, the XPD, and
the Ku 80—transplanted self-renewing capacity not
nearly as well. Furthermore, as they got older, it got
worse, and if you put them directly from young versus
old in a proliferation assay, they did not proliferate as
well, and this further decreased as they got older. In
addition, they undergo apoptosis more then their
counterparts from young mice when they go into their
first cell divisions, and they do not self-renew. Thus,
they have lost in vitro self-renewal capacity.
Next, we wanted to know if there was accumulat-
ing DNA damage in these cells. We looked for dou-
ble-strand breaks and other DNA damage using the
finding that right after a DNA double-strand break,
a rare nucleosome component, H2AX, which is 1 in
6 of the H2As, so it is in 1 of 3 of the nucleosomes,
becomes phosphorylated, creating a megalocus of
H2AXs and triggering the repair process. We X-rayed
the cells, and immediately after we stained for H2 AX
and found increasing numbers of foci with increasing
doses of irradiation. In old mice, there is the equivalent
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worth of breaks that LT HSCs have accumulated.
These foci are largely gone in the multipotent progen-
itors. The explanation for this is that you are accumu-
lating double-strand breaks as you age. For H2 AX
foci, nothing is going to happen unless the cells are
called into cell division. We speculated that exposed
cells either activate the repair process, or go from G0
to G1 and die in the S phase because they have a dou-
ble-strand break, clearing out by death all of those that
were there and that would explain this kind of data.
Leukemic Stem Cells
Many leukemias have translocations as an event
leading to the leukemia, and I have just told you 2
things: (1) aging mice, and perhaps people, have
highly transcriptionally active sites that turn out to
be partners of translocation, and (2) double-strand
breaks accumulate and can reside without repair. I
propose that the coincidence of those 2 developments
leads to nonrandom translocations. Toshihiro Miya-
moto and Koichi Akashi in my lab, hematologists
and bone marrow transplanters from Japan, knew
that at the Hiroshima Hospital they saved viable cell
suspensions of the bone marrow of patients who de-
veloped hematopoietic malignancies. We focused on
those people who had early onset acute myelogenous
leukemia (AML)1-ETO [28]. John Dick and his
group, in a beautiful set of experiments, showed that
he could transplant AML from humans into immuno-
deficient mice [29,30]. He and I had been working on
these mice as xenotransplant recipients in concert for
a long time [29,31]. John showed that the leukemia
would be transferred only with CD341382 cells.
The presumption was that AML was a stem cell dis-
ease, but, as I mentioned previously, CD34,38 is not
sufficient as a marker. We looked at CD34138lo
Thy11 Lin2 HSC and 34138lo Lin2Thy12 cells
that we now know to be multipotent progenitors
(that normally do not self-renew beyond 12 weeks),
and all of the leukemia activity was in the multipotent
progenitor population. They make leukemia blasts, in
vitro, and we now know that they can transplant it.
However, the most important finding was that the
stem cells in those patients do not transplant the dis-
ease; CD341382, Thy1, Lin2 cells make normal mix-
tures of methylcellulose colonies, full distribution, but
up to 40% of them have the AML1-ETO transloca-
tion [28]. Thus, the AML1-ETO translocation may
be necessary for the leukemia that these people got,
but it is not sufficient on its own. Patients can survive
to 150 months at least with 1% of their stem cells still
being AML1-ETO positive. This suggested to us that
one has to have many events in the progression before
one gets an AML. We then looked at a number of leu-
kemias to test this hypothesis.Catriona Jamieson and I looked at polycythemia
vera, and our only question was whether this was a dis-
ease at the level of the stem cell [32]. Emmanuelle Pas-
segue and I had shown in mice that a chronic
myelogenous leukemia could be induced by a JunB
knockout; this myeloproliferative disease was only
transplantable at the level of the hematopoietic stem
cell while it was still a chronic myeloproliferative dis-
ease, but when it went to blast crisis or acute leukemia,
the leukemia was a downstream cell that we could
identify, not the hematopoietic stem cell [33]. Other
people, not us, showed that there is an activated
mutated JAK2 kinase as part of the pathogenesis of
polycythemia vera, this myeloproliferative disease,
and we showed that purified hematopoietic stem cells
from those patients show an abnormal phenotype-
methylcellulose overproduction of red cells and larger
colonies that are blocked with a JAK2 inhibitor. To
summarize all of our experiments in a mouse model,
if we add 1 event after another to try to get to AML,
we have to avoid program cell death every which way
the cell can do it.We used myelomonocytic expression
of Bcl-2, along with a knock out of the fas death path-
way. The leukemias that derive from these mice over-
express CD47, which enhances their mobility and
prevents macrophages from phagocytosing them.
The leukemias that develop only grow in T cell-defi-
cient mice (Jamieson, Jaiswal, and Weissman, unpub-
lished). If you have a functional T cell system they
do not grow, implying immune recognition; these leu-
kemias were transplantable at theGMprogenitor stage
of development, and had turned on beta-catenin ex-
pression. A couple of years ago Tannishta Reya, Karl
Willert, Roeland Nusse, and I showed that the Wnt
pathway was involved in the self-renewal of mouse he-
matopoietic stem cells, and found that if you block the
beta-catenin pathway they cannot self-renew [34,35].
So, in the leukemias I am talking about they are mye-
logenous leukemias and they have activated a self-
renewal component that is used in hematopoiesis
only by the long-term hematopoietic stem cell.
In every example at which we have looked, the first
phase of the leukemia in its chronic form is a disease at
the level of the hematopoietic stem cell. Now, proba-
bly the early phase of AML1-ETO, those Hiroshima
samples, probably they did not come in and complain
of having a translocation only in the hematopoietic
stem cells. But, then the argument goes on that a prog-
eny cell from that has accumulated the 2 or more
events and the leukemia breaks out in its acute phase
at a downstream phase. So, that has been true so far
of the examples I have told you. AML1-ETO has
something going on in the stem cells, but the multipo-
tent progenitor is the acute leukemia. In the mouse
model, the acute leukemia is at the GM progenitor,
but it starts in the hematopoietic stem cell So, Jamie-
son and I got a lot of samples of CML, and we looked
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myeloid blast crisis phase. She noted that in the mye-
loid blast crisis phase, the 1 cell population, beside
the blasts, that were increased in frequency were the
GM progenitors [36], which are several developmental
steps downstream from the hematopoietic stem cell.
We know that CML starts with a multipotent hemato-
poietic cell; Phil Fialkow and colleagues [35] showed
by allelic X chromosomal markers that the CML clone
includes myeloerythroid cells and B cells (but not
T cells). Of course, the canonical bcr-abl translocation
is in these progeny. Catriona and I first showed that
chronic phase CML HSC indeed harbors the translo-
cation. These and normal HSC contained in their
nuclei the unphosphorylated [active] form of beta-
catenin. In the normal or chronic phase GM progeni-
tor, you hardly see it, but it is blazing in the myeloid
blast crisis GM progenitor [37]. Along with Laurie
Ailles, we introduced by lentivirus, a reporter with
LEF-1/TCF (the nuclear partners of beta catenin) ca-
nonical sequences followed by the GFP gene, to test
whether the presence of nuclear catenin resulted in
the reporter being turned on. In this experiment,
GMP in myeloid blast crisis patients, but not from
normal donors, turn on the green protein. The final
point is that normal GM progenitors do not replate
in the methylcellulose assay. If you let them make
the colonies and then replate them, theymakeGM col-
onies but do not renew GMP. The myeloid blast crisis
cells replate just as well as hematopoietic stem cells,
and we could block the replating by introducing into
those myeloid blast crisis, leukemia stem cells, the
pathway inhibitor Axin (expressed at real high levels).Catriona has gone on to show that one can transplant
these leukemias. The GMP from normal mice do not
transplant the disease, but the GM progenitors from
myeloid blast crisis transplant blast crisis serially
from 1 mouse to the next; the blast cells do not trans-
plant the disease. Therefore, it is not the hematopoi-
etic stem cell precursors, nor the blast cell progeny,
but the GM progenitor that is the target and it has
turned on, in addition to bcr-abl, the beta-catenin
pathway. It is also CD471 and has increased levels
of bcl-2, so, there were many events that probably
occurred.
Let me summarize this in a speculative model of
what is happening (Figure 2). Long-term hematopoi-
etic stem cells go to the myeloid series in the quantal
steps of differentiation shown on the top line. The
only self-renewing cell is the long-term HSC. Let us
imagine that if 1 of these cells is bcr-abl, it is a clonal
cell; that we know from our studies, Jamieson and I,
that it becomes the vast majority of the hematopoietic
stem cells in those patients. It does not increase the fre-
quency of stem cells, but rather they have out-com-
peted the cells that do not have bcr-abl [38]. So long
as that clone can exist, we propose that another event
could happen. Let us say that in a bcr-abl HSC sub-
clone you turn on Tert, and then in a further bcr-
abl1, tert1 HSC subclone, you turn on Bcl-2, and
then further along, CD47, or all the events you can
imagine until you have a cell that is able to live long,
keeps proliferating long, has dominated the pool, and
something else happens. And the something else
that happens here, we propose, is that you do not
shut off the beta-catenin system as you go from theFigure 2. Progression to acute myelogenous leukemia (AML) or myeloid blast crisis (CML).
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know that this system is on intrinsically in those cells.
They do not needWnt to drive it, whichmay be an im-
portant point when you plan therapies, eventually. We
know it transplants the disease, and we propose that if
we can isolate in pure form the leukemia stem cells,
which are only 6% of the cells in the bone marrow,
that they and only they have the genetic epigenetic
changes that are shown speculatively in the figure as
events 1, 2, 3, 4, 5, 6, 7, etc.
CONCLUSION
Saying that stem cell biology is important for us to
understand, of course, is something that hematopoietic
stem cell transplanters have been doing all along—
trying to regenerate the system, the hematopoietic sys-
tem. BMT was developed by oncologists, so it is
mainly used for oncologic indications. We hope that
we can move human allogeneic HSC into the therapy
of nonmalignant diseases, because pure HSC cannot
cause any level of GVHD: these cells should be useful
in blocking autoimmune disease and repairing other
genetic diseases of the blood-forming system. Once
you know that hematopoietic stem cells can induce
permanent transplantation tolerance, which we have
shown over and over again, then you should be able
some day to cotransplant hematopoietic stem cells
and liver stem cells, if they exist, or lung, and so on,
and change the way that you treat these diseases.
When we get to the tumor field, I propose that cancer
stem cells (CSCs) are using the same self-renewal
genes that the normal stem cells use, but regulation
of self-renewal is out of control; and these CSCs
have in addition to the hit of the self-renewal gene,
so many other genes that prevent surveillance over
those cells internal or extrinsic. We know that they
have ABC transporters and so they are tougher to get
drugs into. In 2001, Mike Clarke, Tannishta Reya,
Sean Morrison, and I [39] noted that perhaps the
CSCs were more resistant to drugs and radiation
than the majority of cells found in a tumor. Because
remember, all those drugs were found because they
shrunk tumors by maybe 90% to 95%, which did not
mean that in the 90% to 95% were 90% to 95% of
the tumor stem cells. It just meant it shrunk the tumor.
The promise of applying ‘‘stem cell thinking and
approaches’’ to the cancer field is that the isolation of
such cells will allow new insights, new drugs, and
new immune modalities designed to kill CSCs.
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